Breaking the cycle of excitotoxicity: restoring   glutamate balance   to treat CNS disorders

iQure is a clinical-stage biotech company advancing a new therapeutic approach for CNS disorders by restoring glutamate homeostasis.

Our science targets one of the core astrocytic functions -  the regulation of glutamate uptake - essential to maintaining synaptic balance and protecting neurons from overstimulation. By enhancing the function of the main transporter involved in this process, we break the cycle of excitotoxicity - a feedback loop that drives neuronal damage and disease progression across a broad range of CNS conditions.

 

Our lead asset, iQ-007, is a first-in-class, orally available small molecule that enhances the function of the first glutamate transporter. Currently in Phase 1 clinical development for treatment-resistant epilepsy, iQ-007 provides the first clinical validation of our approach. Beyond epilepsy, we are advancing additional preclinical programs targeting neurodegeneration and pain.

iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial — iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial — iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial — iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial — iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial — iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial — iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial — iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial — iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial — iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial —

iQ-007 has entered clinical development  in epilepsy and is currently being evaluated in a Phase 1 trial

OUR TEAM Site visit at Prof. Kamiński’s lab in Krakow with members of the iQure team and early investors. Read more about our team arrow Read more about our team

Our
science

Excitotoxicity is a shared mechanism driving neuronal damage across CNS diseases. It stems from glutamate imbalance - when clearance fails, neurons are exposed to toxic levels.

The main glutamate transporter is responsible for over 90% of glutamate uptake. By enhancing its function, we restore glutamate homeostasis. This mechanism unlocks therapeutic opportunities across multiple indications, including epilepsy, Alzheimer’s Disease, Parkinson’s Disease, and neuroinflammatory conditions such as pain, and traumatic brain injury.

iQure’s approach is demonstrated in peer-reviewed research published in Annals of Neurology 
iQure’s approach is demonstrated in peer-reviewed research published in Annals of Neurology 

Our approach is supported by co-authored research validating our mechanism as a novel antiseizure strategy, with preclinical proof of concept.

The work was conducted in collaboration with Harvard Medical School, NIH, Boston Children’s Hospital, and Jagiellonian University.

iQ-007
breaking the seizure cycle

Explore our pipeline arrow Explore our pipeline
Epilepsy is driven by a reinforcing loop: glutamate accumulation, excitotoxicity, and progressive neuronal damage. The dysfunction of the main glutamate transporter is central to this cycle. iQ-007 is the first clinical-stage compound designed to enhance its activity. By restoring glutamate uptake capacity, it intervenes directly in this pathological feedback mechanism.

The same mechanism is implicated in other CNS conditions, including pain and neurodegeneration.
More about clinical development arrow More about clinical development

Our   investors

decoration